Literature DB >> 19863504

Unique skin changes in a case of Albright hereditary osteodystrophy caused by a rare GNAS1 mutation.

M Klaassens1, E W Blom, J J P Schrander, C Ris-Stalpers, A C Nieuwenhuijzen Kruseman, M A M van Steensel, C T R M Schrander-Stumpel.   

Abstract

Albright hereditary osteodystrophy (AHO) is a syndrome of short stature, obesity, brachydactyly and subcutaneous calcifications with pseudohypoparathyroidism (PHP; leading to hypocalcaemia, hyperphosphataemia and elevated levels of parathyroid hormone, PTH). It was first described over 60 years ago. Since then, much has been learned about the aetiology of AHO which has been shown to be caused by heterozygous loss-of-function mutations within the GNAS1 gene. GNAS1 is subject to imprinting leading to phenotypic heterogeneity within kindreds with one mutation. Patients with AHO often present with symptoms of hypocalcaemia and/or with subcutaneous calcifications. The latter is thought to be the typical skin abnormality in AHO. We describe a family with AHO and hormone resistance (PHP type Ia) resulting from a rare mutation in GNAS1. The proband presented with small subcutaneous calcifications in the helix of the right ear and concentrated in a sharply demarcated zone of subcutaneous and dermal hypoplasia. This abnormality has so far not been described in patients with AHO. We speculate on the mechanism of dermal hypoplasia and resistance to PTH and suggest that subcutanous or dermal hypoplasia might be another feature which can be present in patients with AHO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863504     DOI: 10.1111/j.1365-2133.2009.09543.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

Review 1.  Genodermatoses caused by genetic mosaicism.

Authors:  M Vreeburg; M A M van Steensel
Journal:  Eur J Pediatr       Date:  2012-11-01       Impact factor: 3.183

2.  Impaired iloprost-induced platelet inhibition and phosphoproteome changes in patients with confirmed pseudohypoparathyroidism type Ia, linked to genetic mutations in GNAS.

Authors:  Fiorella A Solari; Oliver Pagel; Frauke Swieringa; Florian Beck; Jingnan Huang; Marion A H Feijge; Kerstin Jurk; Irene M L W Körver-Keularts; Nadine J A Mattheij; Jörg Faber; Joachim Pohlenz; Alexandra Russo; Connie T R M Stumpel; Dirk E Schrander; Barbara Zieger; Paola E J van der Meijden; René P Zahedi; Albert Sickmann; Johan W M Heemskerk
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

Review 3.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.